Literature DB >> 10602719

Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection.

J Piret1, A Désormeaux, P Gourde, J Juhász, M G Bergeron.   

Abstract

The topical efficacies of foscarnet and acyclovir incorporated into a polyoxypropylene-polyoxyethylene polymer were evaluated and compared to that of 5% acyclovir ointment (Zovirax) by use of a murine model of cutaneous herpes simplex virus type 1 infection. All three treatments given three times daily for 4 days and initiated 24 h after infection prevented the development of the zosteriform rash in mice. The acyclovir formulation and the acyclovir ointment reduced the virus titers below detectable levels in skin samples from the majority of mice, whereas the foscarnet formulation has less of an antiviral effect. Reducing the number of treatments to a single application given 24 h postinfection resulted in a significantly higher efficacy of the formulation of acyclovir than of the acyclovir ointment. Acyclovir incorporated within the polymer was also significantly more effective than the acyclovir ointment when treatment was initiated on day 5 postinfection. The higher efficacy of the acyclovir formulation than of the acyclovir ointment is attributed to the semiviscous character of the polymer, which allows better penetration of the drug into the skin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10602719      PMCID: PMC89624          DOI: 10.1128/AAC.44.1.30-38.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group.

Authors:  S L Spruance; T L Rea; C Thoming; R Tucker; R Saltzman; R Boon
Journal:  JAMA       Date:  1997-05-07       Impact factor: 56.272

2.  Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease.

Authors:  A Simmons; A A Nash
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

3.  Topical 5 percent acyclovir in polyethylene glycol for herpes simplex labialis. Antiviral effect without clinical benefit.

Authors:  S L Spruance; C S Crumpacker
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

4.  A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo.

Authors:  J P Luby; J W Gnann; W J Alexander; V A Hatcher; A E Friedman-Kien; R J Klein; H Keyserling; A Nahmias; J Mills; J Schachter
Journal:  J Infect Dis       Date:  1984-07       Impact factor: 5.226

5.  Pathogenesis of zosteriform spread of herpes simplex virus in the mouse.

Authors:  W A Blyth; D A Harbour; T J Hill
Journal:  J Gen Virol       Date:  1984-09       Impact factor: 3.891

6.  Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial.

Authors:  R C Reichman; G J Badger; M E Guinan; A J Nahmias; R E Keeney; L G Davis; T Ashikaga; R Dolin
Journal:  J Infect Dis       Date:  1983-02       Impact factor: 5.226

7.  A trial of topical acyclovir in genital herpes simplex virus infections.

Authors:  L Corey; A J Nahmias; M E Guinan; J K Benedetti; C W Critchlow; K K Holmes
Journal:  N Engl J Med       Date:  1982-06-03       Impact factor: 91.245

8.  Topical treatment of recurrent genital herpes infections with foscarnet.

Authors:  J Wallin; J O Lernestedt; S Ogenstad; E Lycke
Journal:  Scand J Infect Dis       Date:  1985

9.  Relative potencies of different anti-herpes agents in the topical treatment of cutaneous herpes simplex virus infection of athymic nude mice.

Authors:  J Descamps; E De Clercq; P J Barr; A S Jones; R T Walker; P F Torrence; D Shugar
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

Review 10.  Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

Authors:  B Oberg
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

View more
  6 in total

1.  Fabrication of acyclovir-loaded flexible membrane vesicles (FMVs): evidence of preclinical efficacy of antiviral activity in murine model of cutaneous HSV-1 infection.

Authors:  Gajanand Sharma; Kanika Thakur; Arvind Setia; Basant Amarji; Mini P Singh; Kaisar Raza; Om Prakash Katare
Journal:  Drug Deliv Transl Res       Date:  2017-10       Impact factor: 4.617

2.  Efficacies of gel formulations containing foscarnet, alone or combined with sodium lauryl sulfate, against establishment and reactivation of latent herpes simplex virus type 1.

Authors:  J Piret; J Lamontagne; A Désormeaux; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

3.  Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice.

Authors:  J Piret; A Désormeaux; H Cormier; J Lamontagne; P Gourde; J Juhász; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

4.  Topical iontophoresis of valaciclovir hydrochloride improves cutaneous aciclovir delivery.

Authors:  Nada Abla; Aarti Naik; Richard H Guy; Yogeshvar N Kalia
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

5.  Development of novel microemulsion-based topical formulations of acyclovir for the treatment of cutaneous herpetic infections.

Authors:  Sunita Rajan
Journal:  AAPS PharmSciTech       Date:  2009       Impact factor: 3.246

6.  Ginkgolic Acid Inhibits Herpes Simplex Virus Type 1 Skin Infection and Prevents Zosteriform Spread in Mice.

Authors:  Maimoona S Bhutta; Oren Shechter; Elisa S Gallo; Stephen D Martin; Esther Jones; Gustavo F Doncel; Ronen Borenstein
Journal:  Viruses       Date:  2021-01-09       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.